Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat

Safety of fibrates in cholestatic liver diseases

(2021) Andres F. Carrion et al.   LIVER INTERNATIONAL

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges

(2020) Jean-François Dufour et al.   GUT

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

(2020) Stephen A. Harrison et al.   GASTROENTEROLOGY

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

(2020) Rohit Loomba et al.   HEPATOLOGY

CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients

(2019) Paul J. Pockros et al.   LIVER INTERNATIONAL

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis

(2018) Eric J. Lawitz et al.   Clinical Gastroenterology and Hepatology

Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents

(2018) Leigh Goedeke et al.   HEPATOLOGY

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

(2018) Christophe Corpechot et al.   NEW ENGLAND JOURNAL OF MEDICINE

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

(2018) Rohit Loomba et al.   GASTROENTEROLOGY

Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis

(2018) Mary E. Rinella et al.   JOURNAL OF HEPATOLOGY

Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation

(2017) David Goldberg et al.   GASTROENTEROLOGY

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids

(2017) Puneet Puri et al.   HEPATOLOGY

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease

(2014) Stefano Ballestri   WORLD JOURNAL OF GASTROENTEROLOGY

Prevalence of Nonalcoholic Fatty Liver Disease in the United States: The Third National Health and Nutrition Examination Survey, 1988–1994

(2013) Mariana Lazo et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

FXR signaling in the enterohepatic system

(2012) Tsutomu Matsubara et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites

(2010) Brent A. Neuschwander-Tetri   HEPATOLOGY